IS1956B - Meðferð MS sjúkdóms og annarra afmýlimeina með lofepramíni ásamt L-fenýlalaníni, týrósíni eða tryptófani og hugsanlega B12 vítamínsambandi - Google Patents

Meðferð MS sjúkdóms og annarra afmýlimeina með lofepramíni ásamt L-fenýlalaníni, týrósíni eða tryptófani og hugsanlega B12 vítamínsambandi

Info

Publication number: IS1956B
Authority: IS; Iceland
Prior art keywords: phenylalanine; tyrosine; combination; multiple sclerosis; demyelins
Prior art date: 1994-10-05

Application number

IS4454A

Other languages

English (en)

Other versions

IS4454A (is

Inventor

Loder Cari

Original Assignee

Amarin Neuroschience Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-05

Filing date

1997-03-26

Publication date

2004-11-15

1994-10-05 Priority claimed from GB9420116A external-priority patent/GB9420116D0/en

1995-04-26 Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en

1997-03-26 Application filed by Amarin Neuroschience Limited filed Critical Amarin Neuroschience Limited

1997-03-26 Publication of IS4454A publication Critical patent/IS4454A/is

2004-11-15 Publication of IS1956B publication Critical patent/IS1956B/is

Links

OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title abstract 2
201000006417 multiple sclerosis Diseases 0.000 title abstract 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title abstract 2
QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 title 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title 1
229930003779 Vitamin B12 Natural products 0.000 title 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title 1
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 title 1
229960002813 lofepramine Drugs 0.000 title 1
239000011715 vitamin B12 Substances 0.000 title 1
235000019163 vitamin B12 Nutrition 0.000 title 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
229940123445 Tricyclic antidepressant Drugs 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
201000002491 encephalomyelitis Diseases 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
239000003029 tricyclic antidepressant agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Fodder In General (AREA)
Control Of Indicators Other Than Cathode Ray Tubes (AREA)
Control Of El Displays (AREA)

IS4454A 1994-10-05 1997-03-26 Meðferð MS sjúkdóms og annarra afmýlimeina með lofepramíni ásamt L-fenýlalaníni, týrósíni eða tryptófani og hugsanlega B12 vítamínsambandi IS1956B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9420116A GB9420116D0 (en)	1994-10-05	1994-10-05	A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en)	1995-04-26	1995-04-26	A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en)	1994-10-05	1995-10-05	Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (2)

Publication Number	Publication Date
IS4454A IS4454A (is)	1997-03-26
IS1956B true IS1956B (is)	2004-11-15

Family

ID=26305745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4454A IS1956B (is)	1994-10-05	1997-03-26	Meðferð MS sjúkdóms og annarra afmýlimeina með lofepramíni ásamt L-fenýlalaníni, týrósíni eða tryptófani og hugsanlega B12 vítamínsambandi

Country Status (19)

Country	Link
US (2)	US6096737A (is)
EP (1)	EP0784476B1 (is)
JP (1)	JPH10508583A (is)
AT (1)	ATE227124T1 (is)
AU (1)	AU710339B2 (is)
CA (1)	CA2200761C (is)
CZ (1)	CZ293873B6 (is)
DE (1)	DE69528773T2 (is)
DK (1)	DK0784476T3 (is)
ES (1)	ES2184808T3 (is)
FI (1)	FI116659B (is)
HU (1)	HU225493B1 (is)
IS (1)	IS1956B (is)
NO (1)	NO314486B1 (is)
NZ (1)	NZ293642A (is)
PL (1)	PL181802B1 (is)
PT (1)	PT784476E (is)
SK (1)	SK281932B6 (is)
WO (1)	WO1996011009A1 (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0942751B1 (en) *	1996-07-05	2002-09-25	The WWK Trust	Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
GB9617990D0 (en) *	1996-08-29	1996-10-09	Scotia Holdings Plc	Treatment of pain
EP0835660A1 (en) *	1996-10-14	1998-04-15	Gaston Edmond Filomena Merckx	Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) *	1998-06-26	2007-06-19	Elaine A Delack	Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) *	1999-02-24	1999-04-21	Worsley Andrew P	Composition for the treatment of pain
GB9906808D0 (en) *	1999-03-24	1999-05-19	Kilgowan Limited	Formulation for treatment of pain
GB2355191A (en) *	1999-10-12	2001-04-18	Laxdale Ltd	Combination formulations for fatigue, head injury and strokes
CA2774959C (en) *	2000-08-04	2016-05-31	Dmi Biosciences, Inc.	Method of using diketopiperazines and composition containing them
US8394813B2 (en)	2000-11-14	2013-03-12	Shire Llc	Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) *	2001-04-05	2002-10-10	Pfizer Inc.	Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en)	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
US7169752B2 (en) *	2003-09-30	2007-01-30	New River Pharmaceuticals Inc.	Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) *	2002-03-14	2004-12-21	Duane Bennett	Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
US7575929B2 (en)	2002-10-02	2009-08-18	Dmi Life Sciences, Inc.	Diagnosis of multiple sclerosis with diketopiperazines
JP2006517969A (ja) *	2003-02-14	2006-08-03	コンビナトアールエックスインコーポレーティッド	免疫炎症性障害の治療のための組み合わせ療法
CN103191409A (zh)	2003-05-15	2013-07-10	Dmi生物科学公司	T-细胞介导的疾病的治疗
GB0313630D0 (en) *	2003-06-12	2003-07-16	Wwk Trust The	Compositions for the enhanced treatment of depression
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
US20110136742A1 (en) *	2006-02-24	2011-06-09	Travis Mickle	Antidepressant prodrugs
US8217047B2 (en) *	2008-05-27	2012-07-10	Dmi Acquisition Corp.	Therapeutic methods and compounds
WO2011011594A2 (en) *	2009-07-23	2011-01-27	Shriners Hospitals For Children	Intracellular toll-like receptors pathways and axonal degeneration
CA2810844C (en)	2010-09-07	2017-03-21	Dmi Acquisition Corp.	Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
CA2846598C (en)	2011-10-10	2019-12-10	Ampio Pharmaceuticals, Inc.	Treatment of degenerative joint disease
EP2765968A4 (en)	2011-10-10	2015-01-21	Ampio Pharmaceuticals Inc	IMPLANTABLE MEDICINE PRODUCTS WITH INCREASED IMMUNO TOLERANCE AND PROCESSING AND IMPLANTATION METHODS
HK1198812A1 (en)	2011-10-28	2015-06-12	Ampio Pharmaceuticals, Inc.	Treatment of rhinitis
EA201500943A1 (ru)	2013-03-15	2016-08-31	Ампио Фармасьютикалс, Инк.	Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
CA2958080A1 (en)	2014-08-18	2016-02-25	Ampio Pharmaceuticals, Inc.	Treatment of joint conditions
US11389512B2 (en)	2015-06-22	2022-07-19	Ampio Pharmaceuticals, Inc.	Use of low molecular weight fractions of human serum albumin in treating diseases
WO2017085437A1 (en)	2015-11-19	2017-05-26	The Wwk Trust	Combinations for the treatment of dementia, and the enhancement of cognitive function
US20190262353A1 (en) *	2016-10-25	2019-08-29	Uti Limited Partnership	Treatment for progressive multiple sclerosis
WO2018200381A1 (en)	2017-04-25	2018-11-01	Temple Otorongo Llc	Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) *	2017-07-18	2019-01-23	Centre National De La Recherche Scientifique	Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1497306A (en) *	1975-07-03	1978-01-05	Leo Ab	Preparation of lofepramine and its hydrochloride
GB2082910A (en) *	1980-08-28	1982-03-17	Berk Pharmaceuticals Ltd	Anti-depressant compositions
US4409243A (en) *	1981-11-09	1983-10-11	Julian Lieb	Treatment of auto-immune and inflammatory diseases
GB2129299A (en) *	1982-11-09	1984-05-16	Alec James Coppen	Pharmaceutical compositions
DE3519687A1 (de) *	1985-06-01	1986-12-04	Veit Arend	Aminosaeuren enthaltendes arzneimittel
US4650789A (en) *	1985-10-15	1987-03-17	Commonwealth Medical Corporation Of America	Method and composition for increasing production of serotonin
US4843071A (en) *	1986-12-05	1989-06-27	Serotonin Industries Of Charleston	Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) *	1992-02-12	1998-09-24	Kragler Peter	Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

1995
- 1995-10-05 DE DE69528773T patent/DE69528773T2/de not_active Expired - Lifetime
- 1995-10-05 WO PCT/GB1995/002361 patent/WO1996011009A1/en not_active Ceased
- 1995-10-05 HU HU9702373A patent/HU225493B1/hu not_active IP Right Cessation
- 1995-10-05 AT AT95933488T patent/ATE227124T1/de not_active IP Right Cessation
- 1995-10-05 CZ CZ1997995A patent/CZ293873B6/cs not_active IP Right Cessation
- 1995-10-05 PL PL95319830A patent/PL181802B1/pl not_active IP Right Cessation
- 1995-10-05 EP EP95933488A patent/EP0784476B1/en not_active Expired - Lifetime
- 1995-10-05 JP JP8512415A patent/JPH10508583A/ja active Pending
- 1995-10-05 CA CA002200761A patent/CA2200761C/en not_active Expired - Fee Related
- 1995-10-05 US US08/817,086 patent/US6096737A/en not_active Expired - Lifetime
- 1995-10-05 SK SK438-97A patent/SK281932B6/sk not_active IP Right Cessation
- 1995-10-05 PT PT95933488T patent/PT784476E/pt unknown
- 1995-10-05 NZ NZ293642A patent/NZ293642A/xx not_active IP Right Cessation
- 1995-10-05 ES ES95933488T patent/ES2184808T3/es not_active Expired - Lifetime
- 1995-10-05 DK DK95933488T patent/DK0784476T3/da active
- 1995-10-05 AU AU36126/95A patent/AU710339B2/en not_active Ceased
1997
- 1997-03-26 FI FI971290A patent/FI116659B/fi active IP Right Grant
- 1997-03-26 IS IS4454A patent/IS1956B/is unknown
- 1997-04-04 NO NO19971539A patent/NO314486B1/no not_active IP Right Cessation
2000
- 2000-06-01 US US09/584,401 patent/US6569850B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT784476E (pt)	2003-03-31
ATE227124T1 (de)	2002-11-15
JPH10508583A (ja)	1998-08-25
AU3612695A (en)	1996-05-02
FI971290L (fi)	1997-06-02
CA2200761A1 (en)	1996-04-18
US6096737A (en)	2000-08-01
NO971539L (no)	1997-04-04
DE69528773T2 (de)	2003-09-04
ES2184808T3 (es)	2003-04-16
NZ293642A (en)	1998-10-28
NO314486B1 (no)	2003-03-31
PL319830A1 (en)	1997-09-01
NO971539D0 (no)	1997-04-04
DE69528773D1 (de)	2002-12-12
WO1996011009A1 (en)	1996-04-18
CA2200761C (en)	2008-02-26
EP0784476A1 (en)	1997-07-23
CZ99597A3 (en)	1997-11-12
FI116659B (fi)	2006-01-31
AU710339B2 (en)	1999-09-16
SK281932B6 (sk)	2001-09-11
PL181802B1 (en)	2001-09-28
FI971290A0 (fi)	1997-03-26
HU225493B1 (en)	2007-01-29
US6569850B1 (en)	2003-05-27
DK0784476T3 (da)	2003-03-17
HUT77380A (hu)	1998-04-28
CZ293873B6 (cs)	2004-08-18
IS4454A (is)	1997-03-26
EP0784476B1 (en)	2002-11-06
SK43897A3 (en)	1998-08-05

Publication	Publication Date	Title
IS4454A (is)	1997-03-26	Meðferð MS sjúkdóms og annarra afmýlimeina með lofepramíni ásamt L-fenýlalaníni, týrósíni eða tryptófani og hugsanlega B12 vítamínsambandi
NO990279D0 (no)	1999-01-22	Isobutylgaba og dets derivater for behandling av smerte
EP0687175A4 (en)	1997-11-12	METHOD OF TREATING EMOTIONAL OR MENTAL ILLNESS, AND EMOTIONAL OR MENTAL ILLNESS CONCURRENT TO CRISIS
LV11728A (lv)	1997-04-20	Farmaceitiska kompozicija
NO984446L (no)	1998-11-25	FremgangsmÕte for behandling av smerte
NO984196D0 (no)	1998-09-11	Fremgangsmåte for behandling av stoffmisbruk
ES2183977T3 (es)	2003-04-01	Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
RU94033502A (ru)	1996-07-10	Способ лечения детей, больных вторичным панкреатитом
UA10254A (uk)	1996-12-25	Спосіб лікування цукрового діабету
MD950121A (ro)	1996-07-31	Metodă de tratare a urmărilor ictusurilor ischemice
UA29025A (uk)	2000-10-16	Спосіб лікування ендокринної неплідності
UA10740A (uk)	1996-12-25	Спосіб комбіhоваhого лікуваhhя раку шлуhку
EA199800820A1 (ru)	1999-02-25	Способ лечения злоупотребления лекарственными средствами
MX9707038A (es)	1997-11-29	El uso de un agente vasoactivo en la preparacion de composiciones para evitar disfuncion erectil, y equipo para el mismo.
CO4700451A1 (es)	1998-12-29	Dimaleato de n,n-dietil-8, 8-dipropil-2-azaspiro[4.5] decano-2-propanamina
MX9704887A (es)	1998-06-30	Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
UA27148C2 (uk)	2000-02-28	Спосіб лікуваhhя гострого пієлоhефриту
UA49482A (uk)	2002-09-16	Спосіб лікування епілептичної хвороби
RU94045317A (ru)	1996-10-27	Способ лечения вилюйского энцефаломиелита